Welcome to our dedicated page for CLXPF news (Ticker: CLXPF), a resource for investors and traders seeking the latest updates and insights on CLXPF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CLXPF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CLXPF's position in the market.
Cybin Inc. (OTCQB:CLXPF), a biotechnology company focused on psychedelic therapeutics, has announced significant senior management changes to enhance its clinical operations in the U.S. and Europe. Alexander Belser, PhD, becomes Chief Clinical Officer, and Aaron Bartlone takes on the role of Chief Operating Officer. Former COO Paul Glavine will now serve as Chief Growth Officer, while John Kanakis becomes Chief Business Officer. These appointments aim to strengthen Cybin's industry position and broaden its management expertise as it advances mental healthcare initiatives.
Cybin, a biotechnology company focused on psychedelic therapeutics, has announced a new partnership with Catalent, the leader in drug delivery technologies. The agreement allows Cybin to utilize Catalent’s proprietary Zydis® orally disintegrating tablet (ODT) technology for its novel drug CYB003, aimed at treating resistant psychiatric disorders. This innovative delivery method promises improved pharmacokinetics by enabling pre-gastric absorption. The project begins in April 2021 with feasibility studies on various ODT formulations.
Cybin has successfully completed its 20th pre-clinical study and is advancing the proprietary psychedelic molecules CYB003 and CYB004 into Investigational New Drug (IND)-enabling studies. The studies utilized Cybin's technology and were executed rapidly through collaboration with partners. The company has initiated an API manufacturing contract and aims to address serious psychiatric conditions with these new candidates. Cybin boasts a discovery pipeline of over 50 proprietary psychedelic molecules, enhancing its position in the emerging psychedelic therapeutics market.
Cybin, a biotechnology company specializing in psychedelic therapeutics, announced that CEO Doug Drysdale will present a business and pipeline update at the Oppenheimer 31st Annual Healthcare Conference on March 18, 2021, at 11:20 AM Eastern Time. The presentation will also be available via a live webcast for seven days afterward. Cybin is known for its innovative approaches to drug discovery, delivery systems, and psychiatric disorder treatments.
Cybin Inc. (NEO:CYBN, OTCQB:CLXPF), a biotechnology company focused on psychedelic therapeutics, announced that CEO Doug Drysdale will present a business update at the M Vest and Maxim Group 2021 Emerging Growth Virtual Conference on March 17, 2021, at 3:30 PM ET. He will also participate in a panel discussion on psychedelics, which will be webcast live and available for replay for one week. Cybin leverages proprietary drug discovery and delivery systems to develop treatments for psychiatric disorders.
Cybin Inc. has commenced trading on the OTCQB under the symbol ‘CLXPF’ as of March 8, 2021. This move enhances the company's visibility and liquidity, allowing better access to both institutional and retail investors, as highlighted by CEO Doug Drysdale. The OTCQB, recognized by the SEC, offers stricter compliance and quality standards, which could positively impact investor confidence. Cybin continues to trade on the NEO Exchange under the symbol ‘CYBN’ and focuses on developing psychedelic therapeutics for mental health issues.